- Home
- PLL vs NBTX Comparison
PLL vs NBTX Comparison
Compare PLL & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- NBTX
- Stock Information
- Founded
- PLL 2016
- NBTX 2003
- Country
- PLL United States
- NBTX France
- Employees
- PLL N/A
- NBTX N/A
- Industry
- PLL Other Metals and Minerals
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- PLL Basic Materials
- NBTX Health Care
- Exchange
- PLL Nasdaq
- NBTX Nasdaq
- Market Cap
- PLL 184.1M
- NBTX 211.9M
- IPO Year
- PLL 2017
- NBTX 2020
- Fundamental
- Price
- PLL $8.97
- NBTX $9.85
- Analyst Decision
- PLL Hold
- NBTX Strong Buy
- Analyst Count
- PLL 5
- NBTX 1
- Target Price
- PLL $10.31
- NBTX $8.00
- AVG Volume (30 Days)
- PLL 515.6K
- NBTX 15.0K
- Earning Date
- PLL 08-07-2025
- NBTX 09-17-2025
- Dividend Yield
- PLL N/A
- NBTX N/A
- EPS Growth
- PLL N/A
- NBTX N/A
- EPS
- PLL N/A
- NBTX N/A
- Revenue
- PLL $105,102,000.00
- NBTX N/A
- Revenue This Year
- PLL N/A
- NBTX N/A
- Revenue Next Year
- PLL $33.37
- NBTX $74.67
- P/E Ratio
- PLL N/A
- NBTX N/A
- Revenue Growth
- PLL 58.18
- NBTX N/A
- 52 Week Low
- PLL $5.15
- NBTX $2.76
- 52 Week High
- PLL $15.44
- NBTX $10.59
- Technical
- Relative Strength Index (RSI)
- PLL 55.11
- NBTX 75.73
- Support Level
- PLL $8.48
- NBTX $8.20
- Resistance Level
- PLL $9.44
- NBTX $10.59
- Average True Range (ATR)
- PLL 0.58
- NBTX 0.51
- MACD
- PLL -0.07
- NBTX 0.18
- Stochastic Oscillator
- PLL 34.92
- NBTX 79.95
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.